JP2006501295A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501295A5
JP2006501295A5 JP2004540932A JP2004540932A JP2006501295A5 JP 2006501295 A5 JP2006501295 A5 JP 2006501295A5 JP 2004540932 A JP2004540932 A JP 2004540932A JP 2004540932 A JP2004540932 A JP 2004540932A JP 2006501295 A5 JP2006501295 A5 JP 2006501295A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
compound according
halogen
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004540932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501295A (ja
JP4653486B2 (ja
Filing date
Publication date
Priority claimed from GBGB0223038.1A external-priority patent/GB0223038D0/en
Application filed filed Critical
Publication of JP2006501295A publication Critical patent/JP2006501295A/ja
Publication of JP2006501295A5 publication Critical patent/JP2006501295A5/ja
Application granted granted Critical
Publication of JP4653486B2 publication Critical patent/JP4653486B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004540932A 2002-10-04 2003-09-25 ガンマ−セクレターゼ阻害剤としてのシクロヘキシルスルホン Expired - Fee Related JP4653486B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223038.1A GB0223038D0 (en) 2002-10-04 2002-10-04 Therapeutic compounds
PCT/GB2003/004196 WO2004031139A1 (en) 2002-10-04 2003-09-25 Cyclohexyl sulphones as gamma-secretase inhibitors

Publications (3)

Publication Number Publication Date
JP2006501295A JP2006501295A (ja) 2006-01-12
JP2006501295A5 true JP2006501295A5 (enExample) 2006-11-02
JP4653486B2 JP4653486B2 (ja) 2011-03-16

Family

ID=9945312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004540932A Expired - Fee Related JP4653486B2 (ja) 2002-10-04 2003-09-25 ガンマ−セクレターゼ阻害剤としてのシクロヘキシルスルホン

Country Status (9)

Country Link
US (1) US6890956B2 (enExample)
EP (1) EP1551799B1 (enExample)
JP (1) JP4653486B2 (enExample)
AT (1) ATE464287T1 (enExample)
AU (1) AU2003269211C1 (enExample)
CA (1) CA2500969A1 (enExample)
DE (1) DE60332137D1 (enExample)
GB (1) GB0223038D0 (enExample)
WO (1) WO2004031139A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
EP1453516A2 (de) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
AU2002367147A1 (en) 2001-12-27 2003-07-15 Daiichi Pharmaceutical Co., Ltd. Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2526487A1 (en) 2003-06-30 2005-01-06 Daiichi Pharmaceutical Co., Ltd. Heterocyclic methyl sulfone derivative
GB0323258D0 (en) * 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
DE602005012825D1 (de) * 2004-06-16 2009-04-02 Wyeth Corp Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
RU2007126570A (ru) * 2005-01-14 2009-02-20 Вайет (Us) Аминоимидазолоны, применяемые для ингибирования бета-секретазы
US20090215775A1 (en) * 2005-05-17 2009-08-27 Huw David Lewis Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0513747D0 (en) * 2005-07-06 2005-08-10 Merck Sharp & Dohme Therapeutic compounds
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
WO2011053822A2 (en) 2009-11-01 2011-05-05 The Brigham And Women's Hospital, Inc. Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
US8133857B2 (en) * 2006-03-07 2012-03-13 The Brigham and Women's FHospital, Inc. NOTCH inhibition in the treatment of atherosclerosis
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009035522A1 (en) * 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
AU2009239555A1 (en) 2008-04-23 2009-10-29 Merck Sharp & Dohme Corp. Cyclobutyl sulfones as Notch sparing gamma secretase inhibitors
EP2381936B2 (en) 2008-11-24 2020-02-12 Massachusetts Eye & Ear Infirmary Pathways to generate auditory hair cells
EP2393776B1 (en) * 2009-02-06 2014-05-14 Merck Sharp & Dohme Corp. Novel trifluoromethylsulfonamide gamma secretase inhibitor
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2011009064A1 (en) * 2009-07-17 2011-01-20 The J. David Gladstone Institutes Methods of controlling cell proliferation
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
CN102762534A (zh) * 2009-09-18 2012-10-31 扎里卡斯药品有限公司 作为钙通道阻断剂的芳基砜衍生物
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2013059302A1 (en) 2011-10-17 2013-04-25 Nationwide Children's Hospital, Inc. Products and methods for aortic abdominal aneurysm
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
AU2013312305B2 (en) 2012-09-07 2018-06-28 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
EP2925888B1 (en) 2012-11-28 2017-10-25 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015104343A1 (en) * 2014-01-09 2015-07-16 Proyecto De Biomedicina Cima, S.L. New antifibrinolytic compounds
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
MX2018000999A (es) 2015-07-24 2018-11-09 Oncotracker Inc Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico.
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
AU2017212655B2 (en) 2016-01-29 2024-01-18 Decibel Therapeutics, Inc. Expansion and differentiation of inner ear supporting cells and methods of use thereof
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
AU2018222749B2 (en) 2017-02-17 2024-04-18 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3823672A1 (en) 2018-07-19 2021-05-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Combination for treating cancer
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US20230108452A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112022018987A2 (pt) 2020-03-26 2022-11-01 Seagen Inc Métodos de tratamento de mieloma múltiplo
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
PE20251401A1 (es) 2022-09-02 2025-05-22 Merck Sharp And Dohme Llc Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos
AU2023366166A1 (en) 2022-10-25 2025-05-01 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (en) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802013A (en) * 1954-02-12 1957-08-06 Searle & Co 2-(oxo and imino)-3-(phenyl and halophenyl)-tetrahydrofuransulfones and processes for the manufacture thereof
US2812330A (en) * 1956-05-02 1957-11-05 Searle & Co Sulfone derivatives of 2, 6-piperidinedione
CA2191924A1 (en) * 1995-12-05 1997-06-06 Kevin Felsenstein 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of .beta.-amyloid protein production
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
AU2001240861B2 (en) * 2000-03-20 2006-03-30 Merck Frosst Canada Ltd Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
WO2003013527A1 (en) * 2001-08-03 2003-02-20 Schering Corporation Sulfonamide derivatives as gamma secretase inhibitors
AU2002367147A1 (en) 2001-12-27 2003-07-15 Daiichi Pharmaceutical Co., Ltd. Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
DE10201392A1 (de) * 2002-01-16 2003-07-31 Bayer Ag Phenylsulfoxide und-sulfone

Similar Documents

Publication Publication Date Title
JP2006501295A5 (enExample)
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
JP2005501120A5 (enExample)
RU2335493C2 (ru) Производные хинолина в качестве ингибиторов фосфодиэстеразы
JP2007502806A5 (enExample)
JP2024050527A5 (enExample)
RU2006107653A (ru) Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли
JP2019094345A5 (enExample)
ZA200107494B (en) N-cyanomethylamides as protease inhibitors.
JP2005539088A5 (enExample)
JP2004526680A (ja) カリウムチャネル遮断作用を有するアリール化フラン及びチオフェンカルボキサミド
JP2004514707A (ja) オルト−置換およびメタ−置換ビスアリール化合物、その製造法、医薬としてのその使用、並びにそれを含有する医薬製剤
JP2007508360A5 (enExample)
CA2462110A1 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
JP2002513793A5 (enExample)
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2003535843A5 (enExample)
JP2020507589A5 (enExample)
JPWO2023195529A5 (enExample)
JP2006524222A5 (enExample)
JP2007533722A5 (enExample)
JP2004502670A5 (enExample)
JP2007507494A5 (enExample)
RU97102362A (ru) Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола
JP2004532894A5 (enExample)